Skip to main
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 41%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson's operational sales growth reached 11.5% in the fourth quarter of 2025, despite a significant headwind from generic competition for Stelara, highlighting the strength of the company's innovative medicine and medtech divisions following the divestiture of its consumer business. The company's revised revenue and earnings projections for 2026 indicate an expected total revenue of $100.42 billion and earnings per share of $11.52, driven by strong performance in products such as Rybrevant and Tremfya. With the stock demonstrating a robust performance increase of approximately 30% since July 1, 2025, and favorable adjustments to earnings estimates, a positive outlook for Johnson & Johnson's stock persists.

Bears say

Johnson & Johnson faces significant risks that could negatively impact its financial outlook, including potential rapid sales declines from the loss of patent exclusivity and unfavorable launches or data readouts for key pipeline products. Additionally, increasing investor apprehension surrounding macroeconomic issues, such as U.S. drug pricing reform and ongoing litigation related to product liability, could further contribute to volatility in JNJ's stock performance. The combination of these factors suggests a challenging environment that may restrain revenue growth and profitability for the healthcare giant.

JNJ has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 41% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 17 analysts, JNJ has a Buy consensus rating as of Feb 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $225.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $225.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.